Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $818216.0 as the latest value for Q1 2023.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 41.97% to $818216.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $818216.0, a 70.66% decrease, with the full-year FY2022 number at $2.8 million, up 29.79% from a year prior.
  • Depreciation & Amortization (CF) was $818216.0 for Q1 2023 at Marker Therapeutics, up from $813110.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $819883.0 in Q3 2022 to a low of $10514.0 in Q1 2019.
  • A 5-year average of $373357.0 and a median of $502743.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 1325.61% in 2021, then increased 9.35% in 2022.
  • Marker Therapeutics' Depreciation & Amortization (CF) stood at $34215.0 in 2019, then soared by 522.29% to $212916.0 in 2020, then soared by 165.12% to $564488.0 in 2021, then soared by 44.04% to $813110.0 in 2022, then increased by 0.63% to $818216.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Depreciation & Amortization (CF) are $818216.0 (Q1 2023), $813110.0 (Q4 2022), and $819883.0 (Q3 2022).